iRiva Medical, Inc.

iRiva Medical, Inc. , based in the US, focuses on developing and commercializing innovative neuromodulation technology platforms to treat chronic diseases and improve patient outcomes. iRiva Medical, Inc. specializes in advanced neuromodulation technologies aimed at addressing chronic disease management.

The company is headquartered in Minneapolis, US. iRiva Medical was founded by individuals with experience in the medical technology field, although specific details about their previous ventures are not disclosed. The company has successfully completed one deal, with its most recent funding round taking place on November 11, 2025. iRiva Medical develops and commercializes advanced neuromodulation technology platforms aimed at treating patients with chronic diseases.

Their core product offerings focus on innovative therapies designed to address unmet clinical needs affecting large patient populations. These therapies leverage neuromodulation techniques to manage conditions such as chronic pain and acute heart failure, ultimately improving patient outcomes and quality of life. iRiva Medical collaborates with leading clinicians to ensure their products effectively target prevalent chronic conditions, while their technology is positioned for use in healthcare settings across various geographical markets, including North America and Europe. The company's commitment to innovation in medical technology places them at the forefront of enhancing treatment options for patients suffering from significant health challenges.

iRiva Medical is currently in the development stage, having recently closed its initial financing round led by prominent venture capital firms. While specific revenue figures are not disclosed, the company is structured to engage in business-to-business transactions, partnering with healthcare providers and institutions to deliver its neuromodulation solutions. Revenue generation is anticipated to stem from the commercialization of their innovative products, with potential models including direct sales to hospitals and clinics, as well as collaborations with medical device distributors. The transactions may involve a combination of purchase agreements and strategic partnerships aimed at expanding the reach of their flagship neuromodulation therapies, which are designed to meet the needs of patients with chronic diseases.

In November 2025, iRiva Medical, Inc. raised an undisclosed amount of venture funding led by new investor F-Prime, with participation from other new investors Hatteras Venture Partners, Norwest, and Treo Ventures. The company will use the funding to pursue the development and commercialization of innovative neuromodulation technology platforms to treat chronic diseases. Future plans include launching new products designed to enhance treatment methodologies and expanding into international markets, specifically targeting regions in Europe for growth by 2026.